Brightree to Sell to ResMed for $800 Million

Cooley is advising Brightree on its $800 million sale to ResMed, a tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care. Subject to customary closing conditions, the transaction is anticipated to close by the end of June.

"The Brightree team is very excited to join forces with ResMed to help post-acute care providers navigate the inherent complexities of the healthcare system and ensure that patients get the care they need," said Dave Cormack, president and CEO of Brightree.

Brightree, which is majority-owned by global investment firm Battery Ventures, offers cloud-based software that helps customers improve clinical and business performance in the post-acute care industries of home/durable medical equipment, home health, and hospice – all areas with high prevalence of sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

Related Contacts
Alfred Browne Partner, Boston
Heather Harrington Special Counsel, Boston
Adam Chase Partner, Washington, DC
David Walsh Partner, Reston
Elizabeth Lewis Partner, Reston
Eric Tobias Special Counsel, Washington, DC
Michael Rohr Associate, Boston
Taz Hassonjee Associate, Boston
Stephanie Gentile Partner, New York
Kristin Leavy Special Counsel, Washington, DC
Bryan Berman Associate, Colorado